Gilteritinib + Erlotinib
Phase 1/2Terminated 1 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small-Cell Lung Cancer
Conditions
Non-Small-Cell Lung Cancer
Trial Timeline
Sep 8, 2015 → Sep 28, 2016
NCT ID
NCT02495233About Gilteritinib + Erlotinib
Gilteritinib + Erlotinib is a phase 1/2 stage product being developed by Astellas Pharma for Non-Small-Cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02495233. Target conditions include Non-Small-Cell Lung Cancer.
What happened to similar drugs?
7 of 20 similar drugs in Non-Small-Cell Lung Cancer were approved
Approved (7) Terminated (6) Active (9)
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02495233 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Non-Small-Cell Lung Cancer